WOUND MANAGEMENT TECHNOLOGIES, INC. 5
5 · WOUND MANAGEMENT TECHNOLOGIES, INC. · Filed Feb 14, 2014
Insider Transaction Report
Form 5
Rubinfeld Philip J
Director
Transactions
- Purchase
Series C Preferred Stock
2013-12-19$70.00/sh+1,723$120,610→ 1,723 total→ Common Stock (1,723,000 underlying)
Footnotes (1)
- [F1]Each share of Series C Preferred Stock is convertible into 1,000 shares of the issuer's common stock, subject to the effectiveness of an increase in the authorized number of shares of common stock from 100,000,000 to 250,000,000.